CARDIOPHARMA ApS: Financial statements 2026
CVR: 13966273
Source: annual report 2026, Danish Business Authority
01/05/2025 – 30/04/2026
CARDIOPHARMA ApS (CVR 13966273) has filed annual accounts for 2026. In 2026, the company reported a gross profit of DKK 4,336,132 and a net result of DKK 3,090,043 compared with DKK 1,968,388 the year before. That is an increase of 63.5% compared with the year before. Equity in the 2026 report amounted to DKK 31,593,726. The solvency ratio was 99.9%.
- Revenue
- DKK 0
- Gross Profit
- DKK 4,336,132
- Profit/Loss
- DKK 3,090,043
- Equity
- DKK 31,593,726
- Total Assets
- DKK 31,633,369
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2026 | 0 | 4.3M | 3.1M | 31.6M | 0 |
| 2025 | 0 | 2.7M | 2M | 28.5M | 0 |
| 2024 | 0 | 2.6M | 2.9M | 28.3M | 0 |
| 2023 | 0 | 438K | 1M | 28M | 1 |
| 2022 | 0 | 3.4M | 2.9M | 28M | 1 |
Official annual report
Find more companies like CARDIOPHARMA ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorAbout CARDIOPHARMA ApS
CARDIOPHARMA ApS is a Danish company of the type Anpartsselskab based in Gentofte, founded in 1990. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named KM 455 ApS. The management consists of Niels Christian Fischer Petersen. The company is owned by Niels Christian Fischer Petersen. According to the 2026 annual report, the company had an average of 0 employees. In 2026, the company reported a gross profit of DKK 4,336,132 and a net result of DKK 3,090,043 compared with DKK 1,968,388 the year before. Equity in the 2026 report amounted to DKK 31,593,726.